Neurocrine Biosciences (NBIX) has drawn investor attention after reporting new two year Phase 3 data for CRENESSITY in both adults and children with classic congenital adrenal hyperplasia, reinforcing the therapy’s real world clinical profile.

The stock has been working through mixed momentum, with a 5.42% 7 day share price return and a 2.63% 30 day share price return offset by a 3.94% year to date share price decline. The 1 year total shareholder return of 13.57% reflects a stronger longer run picture as recent CRENESSITY data and the new obesity program keep attention on Neurocrine’s pipeline progress.

If this type of pipeline driven story interests you, it could be worth broadening your search with our screener of 35 healthcare AI stocks.

With Neurocrine trading at US$135.06 and sitting on a market cap of about US$13.5b, yet screening on some models as materially below intrinsic value and analyst targets, is the market overlooking future growth or already factoring it in?

Most Popular Narrative: 27.6% Undervalued

Neurocrine Biosciences' most followed narrative pegs fair value at about $186.45, well above the last close at $135.06, with the gap anchored in expectations around its core neurology franchises and expanding pipeline.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Curious what kind of revenue and earnings profile would support that higher fair value, and what future profit multiple this narrative assumes? The full story links detailed growth forecasts, margin expansion, and a higher earnings base to justify that gap to fair value.

Result: Fair Value of $186.45 (UNDERVALUED)

However, this hinges on INGREZZA and CRENESSITY continuing to perform as expected, while pricing pressure and tighter payer controls could still challenge those long term earnings assumptions.

Another Angle: Multiples Point to a Richer Price Tag

That 27.6% “undervalued” narrative sits uncomfortably next to what the current P/E suggests. Neurocrine trades on about 28.4x earnings, compared with 17.2x for the US Biotechs industry, 20.5x for peers, and a fair ratio of 23x. In plain terms, the stock already carries a premium. This raises the question of whether the upside story is fully reflected in today’s multiple.

For a closer look at how this premium compares to the ratios the market could shift toward over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals in this story leave you undecided, now is a good time to check the underlying details, stress test the numbers, and form your own take on the company’s potential rewards by reviewing the 4 key rewards

Looking for more investment ideas?

If Neurocrine has caught your eye, do not stop here. Use this momentum to widen your watchlist with other high quality, well screened opportunities.

• Zero in on companies that look attractively priced relative to fundamentals by scanning our 50 high quality undervalued stocks.
• Prioritize resilience and capital protection by reviewing companies in the 72 resilient stocks with low risk scores.
• Get ahead of the crowd by spotting lesser known opportunities using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.